Frontiers in Immunology (Dec 2021)
SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination
- Yudi T. Pinilla,
- Yudi T. Pinilla,
- Constanze Heinzel,
- Constanze Heinzel,
- Lena-Fabienne Caminada,
- Douglas Consolaro,
- Douglas Consolaro,
- Meral Esen,
- Meral Esen,
- Meral Esen,
- Meral Esen,
- Peter G. Kremsner,
- Peter G. Kremsner,
- Peter G. Kremsner,
- Jana Held,
- Jana Held,
- Jana Held,
- Andrea Kreidenweiss,
- Andrea Kreidenweiss,
- Andrea Kreidenweiss,
- Rolf Fendel,
- Rolf Fendel,
- Rolf Fendel
Affiliations
- Yudi T. Pinilla
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Yudi T. Pinilla
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- Constanze Heinzel
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Constanze Heinzel
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- Lena-Fabienne Caminada
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Douglas Consolaro
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Douglas Consolaro
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- Meral Esen
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Meral Esen
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- Meral Esen
- Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
- Meral Esen
- Cluster of Excellence: Exzellenzcluster (EXC) 2124: Controlling Microbes to Fight Infection, Tübingen, Germany
- Peter G. Kremsner
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Peter G. Kremsner
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- Peter G. Kremsner
- Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
- Jana Held
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Jana Held
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- Jana Held
- Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
- Andrea Kreidenweiss
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Andrea Kreidenweiss
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- Andrea Kreidenweiss
- Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
- Rolf Fendel
- Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
- Rolf Fendel
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- Rolf Fendel
- Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
- DOI
- https://doi.org/10.3389/fimmu.2021.798859
- Journal volume & issue
-
Vol. 12
Abstract
SARS-CoV-2 antibodies in saliva serve as first line of defense against the virus. They are present in the mucosa, more precisely in saliva, after a recovered infection and also following vaccination. We report here the antibody persistence in plasma and in saliva up to 15 months after mild COVID-19. The IgG antibody response was measured every two months in 72 participants using an established and validated in-house ELISA assay. In addition, the virus inhibitory activity of plasma antibodies was assessed in a surrogate virus neutralization test before and after vaccination. SARS-CoV-2-specific antibody concentrations remained stable in plasma and saliva and the response was strongly boosted after one dose COVID-19 vaccination.
Keywords